David Wilkinson

Summary

Affiliation: Memory Assessment and Research Centre
Country: UK

Publications

  1. ncbi Donepezil in vascular dementia: a randomized, placebo-controlled study
    D Wilkinson
    Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, UK
    Neurology 61:479-86. 2003
  2. ncbi The role of general practitioners in the diagnosis and treatment of Alzheimer's disease: a multinational survey
    D Wilkinson
    Memory Assessment and Research Centre, Southampton, UK
    J Int Med Res 32:149-59. 2004
  3. ncbi Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy
    David G Wilkinson
    Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, UK
    Drugs Aging 21:453-78. 2004
  4. ncbi Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease
    David Wilkinson
    Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, UK
    Dement Geriatr Cogn Disord 24:138-45. 2007
  5. pmc Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer's disease
    David Wilkinson
    Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, UK
    Dement Geriatr Cogn Disord 28:244-51. 2009
  6. doi A review of the effects of memantine on clinical progression in Alzheimer's disease
    David Wilkinson
    Memory Assessment and Research Centre MARC, Moorgreen Hospital, Southampton, UK
    Int J Geriatr Psychiatry 27:769-76. 2012
  7. doi Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial
    David Wilkinson
    Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, UK
    J Alzheimers Dis 29:459-69. 2012
  8. doi The long-term efficacy and tolerability of donepezil in patients with vascular dementia
    David Wilkinson
    Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, UK
    Int J Geriatr Psychiatry 25:305-13. 2010
  9. doi Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
    Clive Holmes
    Division of Clinical Neurosciences, University of Southampton, Southampton, UK Moorgreen Hospital, Hampshire Partnership Trust, Southampton, UK
    Lancet 372:216-23. 2008
  10. ncbi Abeta species removal after abeta42 immunization
    James A R Nicoll
    Division of Clinical Neurosciences, School of Medicine, University of Southampton, Southampton, UK
    J Neuropathol Exp Neurol 65:1040-8. 2006

Detail Information

Publications14

  1. ncbi Donepezil in vascular dementia: a randomized, placebo-controlled study
    D Wilkinson
    Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, UK
    Neurology 61:479-86. 2003
    ..To evaluate the efficacy and tolerability of donepezil in patients with vascular dementia (VaD)...
  2. ncbi The role of general practitioners in the diagnosis and treatment of Alzheimer's disease: a multinational survey
    D Wilkinson
    Memory Assessment and Research Centre, Southampton, UK
    J Int Med Res 32:149-59. 2004
    ..Access to AD care is restricted by many national healthcare systems. The delay in diagnosis imposed by such restrictions impacts on access to early and effective treatment...
  3. ncbi Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy
    David G Wilkinson
    Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, UK
    Drugs Aging 21:453-78. 2004
    ....
  4. ncbi Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease
    David Wilkinson
    Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, UK
    Dement Geriatr Cogn Disord 24:138-45. 2007
    ..Alzheimer's disease (AD) is a progressive neurodegenerative disorder and delaying disease worsening is a relevant treatment outcome...
  5. pmc Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer's disease
    David Wilkinson
    Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, UK
    Dement Geriatr Cogn Disord 28:244-51. 2009
    ..Therapeutic endpoints based on reduced clinical worsening represent clinically relevant and realistic goals for patients suffering from progressive neurodegenerative disorders such as Alzheimer's disease (AD)...
  6. doi A review of the effects of memantine on clinical progression in Alzheimer's disease
    David Wilkinson
    Memory Assessment and Research Centre MARC, Moorgreen Hospital, Southampton, UK
    Int J Geriatr Psychiatry 27:769-76. 2012
    ..If given early, such a treatment would be expected to maximise any potential benefit. Memantine has shown clinical benefits in the key domains of AD, both as monotherapy and in combination with a cholinesterase inhibitor (ChEI)...
  7. doi Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial
    David Wilkinson
    Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, UK
    J Alzheimers Dis 29:459-69. 2012
    ..The biological relevance of cerebral atrophy was supported by a significant correlation between rate of atrophy and decline in cognitive and behavioral outcomes...
  8. doi The long-term efficacy and tolerability of donepezil in patients with vascular dementia
    David Wilkinson
    Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, UK
    Int J Geriatr Psychiatry 25:305-13. 2010
    ..To determine the long-term tolerability and efficacy of donepezil in patients with vascular dementia (VaD)...
  9. doi Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
    Clive Holmes
    Division of Clinical Neurosciences, University of Southampton, Southampton, UK Moorgreen Hospital, Hampshire Partnership Trust, Southampton, UK
    Lancet 372:216-23. 2008
    ..Our aim was to assess the relation between Abeta(42) immune response, degree of plaque removal, and long-term clinical outcomes...
  10. ncbi Abeta species removal after abeta42 immunization
    James A R Nicoll
    Division of Clinical Neurosciences, School of Medicine, University of Southampton, Southampton, UK
    J Neuropathol Exp Neurol 65:1040-8. 2006
    ..Abeta immunotherapy can clear all Abeta species from the cortex. However, if it is to be used for treatment of established Alzheimer disease, then the residual tau pathology and cerebral amyloid angiopathy require further study...
  11. ncbi Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report
    James A R Nicoll
    Division of Clinical Neurosciences, University of Southampton, Southampton, UK
    Nat Med 9:448-52. 2003
    ..The T-lymphocyte meningoencephalitis is likely to correspond to the side effect seen in some other patients who received AN-1792 (refs. 7-9)...
  12. ncbi Prophylactic therapy with lithium in elderly patients with unipolar major depression
    David Wilkinson
    MARC, Elderly Mental Health Directorate, Moorgreen Hospital, Southampton
    Int J Geriatr Psychiatry 17:619-22. 2002
    ..To compare the relapse rate of elderly depressed patients taking low dose lithium as an additional therapy with antidepressant medication to those receiving antidepressant medication alone...
  13. ncbi Donepezil in vascular dementia: combined analysis of two large-scale clinical trials
    Gustavo C Roman
    Department of Medicine Neurology, University of Texas Health Science Center and Audie Murphy Veterans Hospital, San Antonio, Tex 78229 3900, USA
    Dement Geriatr Cogn Disord 20:338-44. 2005
    ..There are currently no drugs approved to treat vascular dementia (VaD). The objective of this study was to determine if treatment with donepezil, an acetylcholinesterase inhibitor, may provide benefit for VaD patients...
  14. ncbi Switching from donepezil to galantamine: a double-blind study of two wash-out periods
    David G Wilkinson
    Int J Geriatr Psychiatry 20:489-91. 2005